Description
Introducing Abretone, a cutting-edge medication manufactured by Cadila Pharmaceuticals Ltd., featuring the active substance Abiraterone Acetate. Recognized internationally under the brand name Zytiga, Abretone is a potent therapeutic option for the management of advanced prostate cancer, offering hope and improved quality of life for patients facing this challenging condition.
Key Features:
- Abiraterone Acetate Potency: Abretone contains Abiraterone Acetate, a potent and selective inhibitor of androgen biosynthesis. Abiraterone works by inhibiting the enzyme cytochrome P450 17α-hydroxylase (CYP17), thereby blocking the production of androgens, including testosterone and dihydrotestosterone (DHT), which fuel the growth of prostate cancer cells.
- Treatment of Advanced Prostate Cancer: Abretone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men who have received prior docetaxel chemotherapy. It is also approved for use in combination with prednisone or prednisolone for the treatment of metastatic castration-sensitive prostate cancer (mCSPC).
- Comprehensive Cancer Therapy: Abretone represents a cornerstone in the treatment of advanced prostate cancer, offering patients a comprehensive therapeutic approach to combat the disease. By targeting androgen signaling pathways, Abiraterone helps slow disease progression, prolong survival, and improve quality of life for patients with advanced prostate cancer.
- Strength and Dosage Form: Abretone is available in a convenient tablet form, with each tablet containing 250 mg of Abiraterone Acetate. The pack comprises 120 tablets, providing patients with an ample supply of medication to support their treatment regimen.
- Manufactured by Cadila Pharmaceuticals Ltd.: Abretone is manufactured by Cadila Pharmaceuticals Ltd., a reputable pharmaceutical company known for its commitment to quality, innovation, and patient care. Each tablet undergoes rigorous quality control measures to ensure purity, potency, and safety, providing patients with a reliable and trusted treatment option for advanced prostate cancer.
Prescription Required: Please note that Abretone is a prescription medication, and its use should be initiated and monitored under the guidance of a qualified healthcare professional.
Empower yourself with Abretone, a trusted therapeutic option for advanced prostate cancer manufactured by Cadila Pharmaceuticals Ltd. With its potent Abiraterone Acetate formulation and comprehensive treatment approach, Abretone offers hope for patients battling advanced prostate cancer, enabling them to live fuller, healthier lives. Choose Cadila Pharmaceuticals Ltd. for reliable and effective cancer therapy that prioritizes patient well-being.
Reviews
There are no reviews yet.